AstraZeneca plc (ADR) (NYSE:AZN) (LON:AZN), one of the leading pharmaceutical companies in the United Kingdom, agreed to pay $50 million to Merck & Co., Inc. (NYSE:MRK) to receive the license for an experimental cancer drug.
AstraZeneca and Merck agreement terms
Under the terms of the agreement, Merck & Co., Inc. (NYSE:MRK) will also receive additional fees related to the development and regulatory milestone, sales-related payments, and tiered royalties. AstraZeneca plc (ADR) (NYSE:AZN) (LON:AZN) will be responsible for all future clinical development, manufacturing and marketing of the medicine.
A few years ago, crypto hedge funds were all the rage. As cryptocurrencies rose in value, hundreds of hedge funds specializing in digital assets launched to try and capitalize on investor demand. Some of these funds recorded double-digit gains in 2020 and 2021 as cryptocurrencies surged in value. However, this year, cryptocurrencies have been under Read More
Iain D. Dukes, senior vice president and head of licensing and external scientific affairs at Merck & Co., Inc. (NYSE:MRK)said, “We are pleased to enter this agreement with AstraZeneca to realise the potential of MK-1775 while we focus on advancing our later stage oncology programs, MK-3475 and vintafolide.” He also stressed the company’s commitment in advancing potentially meaningful therapeutic options for cancer patients.
According to AstraZeneca plc (ADR) (NYSE:AZN) (LON:AZN), the transaction depends on the expiration or termination of the waiting period under the Hart Scott-Rodino Antitrust Improvement Act.
The experimental cancer drug, a small molecule inhibitor of WEEI kinase called MK-1775, is under evaluation in Phase II clinical studies combined with care therapies intended to treat patients afflicted with certain types of ovarian cancer.
AstraZeneca plc (ADR) (NYSE:AZN) (LON:AZN) explained that the WEE1 helps regulate cell division cycle. The WEE1 inhibitor MK-1775 is designed to divide certain tumor cells without going through the normal DNA processes and eventually lead to cell death. Pre-clinical evidences showed the combination of MK-1775 and DNA damage-inducing chemotherapy agents enhance anti-tumor properties as compared to chemotherapy alone.
According to Susan Galbraith, head of Oncology Innovative Medicines Unit at AstraZeneca plc (ADR) (NYSE:AZN) (LON:AZN), “MK-1775 is a strong addition to AstraZeneca’s growing oncology pipeline, which already includes a number of inhibitors of the DNA damage response. The compound has demonstrated encouraging clinical efficacy data and we intend to study it in a range of cancer types where there is a high unmet medical need.”
In June, AstraZeneca plc (ADR) (NYSE:AZN) (LON:AZN) acquired Pearl Therapeutics, a respiratory drug specialist for $1.15 billion, in order to expand its business in emerging markets with LABA/LAMA drugs for the treatment of chronic obstructive pulmonary disease (COPD). Approximately 210 million people suffer from COPD worldwide.